Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Seeking Alpha
Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma. I'm the CEO of Maze Therapeutics. And first of all, I'd like to thank the Jefferies team for inviting us to this year's conference. I'd also like to acknowledge our forward-looking statements. At Maze, our mission is simple, yet ambitious, to harness the power of human genetics to transform the lives of patients. An emphasis for us is chronic kidney disease. Kidney disease is a silent killer. Over 800 million individuals globally suffer from this disease. It's the 9th leading cause of death to date. In some countries, there are -- there is a 4-year waiting list for kidney transplants. And there has been little innovation and no precision medicine approaches for kidney disease. And that is where Maze fits in. We develop small molecules using our genetics approach to really be able to focus on kidney disease. Now our small molecules start with MZE829. That's for
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Maze Therapeutics (NASDAQ:MAZE) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.MarketBeat
MAZE
Earnings
- 11/6/25 - Beat
MAZE
Sec Filings
- 12/4/25 - Form 144
- 11/21/25 - Form 4
- 11/21/25 - Form 144
- MAZE's page on the SEC website